🧪
hypothesis

TFEB Activation to Restore Lysosomal Biogenesis in Aged Synapses

Hypothesis

TFEB Activation to Restore Lysosomal Biogenesis in Aged Synapses

TFEB (together with TFE3 and TFEB family members) is a master transcriptional regulator of lysosomal biogenesis and autophagy.
🧬 TFEB (TFE3, TFE4 family)🩺 proteomics🎯 Composite 59%💱 $0.55▲3.8%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 6 support 6 oppose
✓ All Quality Gates Passed
Mechanistic 0.75 (15%) Evidence 0.57 (15%) Novelty 0.55 (12%) Feasibility 0.55 (12%) Impact 0.70 (12%) Druggability 0.50 (10%) Safety 0.45 (8%) Competition 0.55 (6%) Data Avail. 0.60 (5%) Reproducible 0.55 (5%) KG Connect 0.50 (8%) 0.591 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite59%

🧪 Overview

TFEB (together with TFE3 and TFEB family members) is a master transcriptional regulator of lysosomal biogenesis and autophagy. In aged synapses, lysosomal degradation is often impaired, a defect reflected by autophagosome accumulation despite intact initiation (PMID:30401736). In Alzheimer’s disease (AD) brain tissue, mTOR hyperactivation prevents TFEB nuclear translocation, limiting lysosomal gene expression (PMID:29079772). Pharmacologic inhibition of mTOR with rapamycin analogs or direct overexpression of TFEB can promote nuclear TFEB localization and has been shown to reduce tau aggregation and Aβ toxicity in cellular models (PMID:25661182). Moreover, TFEB activation can bypass upstream mTOR dysregulation and directly drive expression of lysosomal hydrolases and membrane proteins (PMID:31835980). However, TFEB governs a broad transcriptional network that includes lipid metabolism and inflammatory pathways (PMID:28628114), and global or neuron‑non‑specific overexpression can exacerbate neurodegeneration in α‑synuclein models via APP‑like substrate processing (PMID:31225475).

...

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["mTORC1 Hyperactivation<br/>Nutrient/Growth Signals"]
    B["TFEB Phosphorylation<br/>Ser211 by mTORC1"]
    C["14-3-3 Sequestration<br/>Cytoplasmic Retention"]
    D["Lysosomal Biogenesis<br/>Blocked"]
    E["Autophagic Flux<br/>Impaired"]
    F["Tau/Amyloid Aggregate<br/>Accumulation"]
    G["TFEB Activation<br/>Rapamycin or MCOLN1"]
    H["Nuclear TFEB<br/>CLEAR Gene Expression"]
    G --> H
    H -.->|"rescues"| D
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style G fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style H fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix6 supports6 contradicts
Supports
TFEB overexpression reduces tau aggregation and Aβ toxicity in cellular models
PMID:25661182
Supports
Impaired TFEB nuclear localization observed in AD brain tissue with mTOR hyperactivation
PMID:29079772
Supports
Trehalose enhances lysosomal biogenesis and reduces protein aggregates in neurodegeneration models
PMID:25205291
Supports
Autophagosome accumulation in AD synapses indicates upstream autophagy initiation is intact but downstream lysosomal degradation is blocked
PMID:30401736
Supports
mTOR inhibitors (rapamycin analogs) enable TFEB nuclear translocation
PMID:30629572
Supports
TFEB activation bypasses upstream mTOR dysregulation and directly enhances lysosomal gene expression
PMID:31835980
Contradicts
TFEB regulates hundreds of genes beyond lysosomal biogenesis including lipid metabolism and inflammatory pathways
PMID:28628114
Contradicts
TFEB overexpression paradoxically increases neurodegeneration in α-synuclein models via APP-like substrate processing
PMID:31225475
Contradicts
Global TFEB activation in microglia exacerbates neuroinflammation through enhanced lysosomal antigen presentation
PMID:33004405
Contradicts
TFEB haploinsufficiency is protective in certain aging paradigms, suggesting a 'Goldilocks' principle
PMID:30459173
Contradicts
Trehalose acts as chemical chaperone independently of TFEB
PMID:28628114
Contradicts
Genistein is a broad kinase inhibitor with estrogenic activity
PMID:19337990
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — TFEB

No curated PDB or AlphaFold mapping for TFEB yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for TFEB (TFE3, TFE4 family) from GTEx v10.

Spinal cord cervical c-127.0 Cerebellum11.3median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for TFEB (TFE3, TFE4 family) →

No DepMap CRISPR Chronos data found for TFEB (TFE3, TFE4 family).

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.7%
Volatility
Medium
0.0296
Events (7d)
3
Price History
▲3.8%

💾 Resource Usage

LLM Tokens
39,448
$0.1183
Total Cost
$0.1183

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF pharmacologically activate TFEB using a selective agonist (e.g., trehalose or novel synthetic activator) in primary hippocampal neurons cultured from aged (18-24 month) C57BL/6 mice, THEN lysosomalIncreased lysosomal biogenesis and synaptic protein levels in aged neurons following TFEB activation— no observation —pending0.58
IF genetically overexpress TFEB via AAV9-mediated delivery in the hippocampus of aged (20-22 month) C57BL/6 mice, THEN lysosomal proteostasis markers (LC3-II/LC3-I ratio, Cathepsin D levels) will normRestoration of lysosomal proteostasis and improvement in spatial memory performance following TFEB overexpression in aged mice— no observation —pending0.52
🔮 Falsifiable Predictions (2)
pendingconf 58%
IF pharmacologically activate TFEB using a selective agonist (e.g., trehalose or novel synthetic activator) in primary hippocampal neurons cultured from aged (18-24 month) C57BL/6 mice, THEN lysosomal biogenesis markers (LAMP1 density, cathepsin D activity) will increase by ≥40% AND synaptic protein
Predicted outcome: Increased lysosomal biogenesis and synaptic protein levels in aged neurons following TFEB activation
Falsification: No significant change or decrease in lysosomal markers AND/OR no improvement or reduction in synaptic proteins compared to vehicle-treated aged neurons; any increase <20% for lysosomal markers or <15%
pendingconf 52%
IF genetically overexpress TFEB via AAV9-mediated delivery in the hippocampus of aged (20-22 month) C57BL/6 mice, THEN lysosomal proteostasis markers (LC3-II/LC3-I ratio, Cathepsin D levels) will normalize to young adult levels AND cognitive performance on Morris water maze will improve by ≥30% comp
Predicted outcome: Restoration of lysosomal proteostasis and improvement in spatial memory performance following TFEB overexpression in aged mice
Falsification: No significant increase in lysosomal markers or any worsening of cognitive performance; improvement <15% in water maze latency would not support the hypothesis; hippocampal protein levels must show ≥3
View on SciDEX ↗